MDVerse develops regenerative medicine for drug development, manufacturing, and clinical trials.
MDVerse has raised $750K in total funding. The most recent round was Seed. The last funding was announced in January 2023.
MDVerse's investors include PGV.
MDVerse is headquartered in Fremont, United States.
MDVerse develops regenerative medicine for drug development, manufacturing, and clinical trials.
MDVerse is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MDVerse — Funding & Investors." VCBacked, January 1, 2023, https://www.vcbacked.co/company/mdverse. Accessed August 1, 2026.
VCBacked. (2023). MDVerse — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/mdverse
{{cite web |title=MDVerse — Funding & Investors |url=https://www.vcbacked.co/company/mdverse |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated